Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELEVATE trial of atogepant for preventive treatment of episodic migraine after prior oral preventive treatment failures
2019-003448-58Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in episodic migraine comparing Atogepant with Placebo (2 arms). Primary endpoint: Change from baseline in mean monthly migraine days across the 12-week treatment period. Started May 2020; status: completed.
02
Drugs
atogepant
03
Conditions
episodic migraine
Beyond the preview
Go deeper on 2019-003448-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003448-58.